Pharmacodynamics<unk>  acts as a nonselective and irreversible inhibitor of monoamine oxidase. Regarding the isoforms of monoamine oxidase, it shows slight preference for the MAOB isoenzyme over MAOA. This leads to an increase in the availability of monoamines, such as serotonin, norepinephrine, and dopamine, as well as a marked increase in the availability of trace amines, such as tryptamine, octopamine, and phenethylamine. The clinical relevance of increased trace amine availability is unclear. It may also act as a norepinephrine reuptake inhibitor at higher therapeutic doses. Compared to amphetamine,<unk>  shows low potency as a dopamine releasing agent, with even weaker potency for norepinephrine and serotonin release.<unk>  has also been shown to inhibit the histone demethylase, BHC110/LSD1.<unk>  inhibits this enzyme with an IC50 max) within 1–2 hours. After a 20 mg dose, plasma concentrations reach at most 50-200 ng/mL. While its half-life is only about 2 hours, its pharmacodynamic effects last several days to weeks due to irreversible inhibition of MAO. Metabolites of<unk>  include 4-hydroxytranylcypromine, N-acetyltranylcypromine, and N-acetyl-4-hydroxytranylcypromine, which are less potent MAO inhibitors than<unk>  itself. Amphetamine was once thought to be a metabolite of<unk> , but has not been shown to be.<unk>  inhibits CYP2A6 at therapeutic concentrations.
Tranylcypromine
Patiromer
Dimethazan
Veristrat
Bretylium
Rauwolscine
Levomethamphetamine
Propylamphetamine